TP53 germline mutations in Portugal and genetic modifiers of age at cancer onset

被引:0
|
作者
Carla Pinto
Isabel Veiga
Manuela Pinheiro
Ana Peixoto
Armando Pinto
José M. Lopes
Rui M. Reis
Carla Oliveira
Manuela Baptista
Lúcia Roque
Fernando Regateiro
Luís Cirnes
Robert M. W. Hofstra
Raquel Seruca
Sérgio Castedo
Manuel R. Teixeira
机构
[1] Portuguese Oncology Institute,Department of Genetics
[2] Portuguese Oncology Institute,Department of Pediatrics
[3] Portuguese Oncology Institute,Department of Oncology
[4] University of Minho,Life and Health Sciences Research Institute (ICVS), School of Health Sciences
[5] Institute of Molecular Pathology and Immunology of Porto University (IPATIMUP),Faculty of Medicine
[6] Porto University,Department of Surgery
[7] S. João Hospital,CIPM
[8] Portuguese Oncology Institute,Department of Genetics
[9] Coimbra University Hospital,Abel Salazar Biomedical Sciences Institute (ICBAS)
[10] Groningen University Medical Center,undefined
[11] Porto University,undefined
来源
Familial Cancer | 2009年 / 8卷
关键词
germline mutations; MDM2-SNP309; TP53-72Arg; Telomere length;
D O I
暂无
中图分类号
学科分类号
摘要
The Li-Fraumeni syndrome (LFS) is a rare, autosomal dominant disease caused by TP53 germline mutations. This study aimed to characterize the TP53 mutational spectrum in patients suspected to have LFS in Portugal and to evaluate the influence of the MDM2-SNP309 and TP53-72Arg variants and of telomere length on age of tumor onset. Probands were primarily selected using the classical LFS criteria (two cases) or the more sensitive Chompret Li-Fraumeni-like (LFL) criteria (13 cases), but 12 additional patients that did not comply with those LFS or LFL criteria were included in the analysis based on clinical suspicion (LFS suspects). Nine of the 27 probands (33.3%) presented germline TP53 mutations, two of them occurring de novo and two of them being novel. Three of the nine TP53 mutations were found in families that did not comply with any of the commonly used criteria for TP53 testing, leaving room to recommend the use of less stringent criteria. An association was found between the presence of the TP53-72Arg (but not the MDM2-SNP309) variant and earlier age of onset in TP53 carriers. A negative correlation between telomere length and age of cancer onset was found in patients with germline TP53 mutation, whereas no such correlation was found in controls or in patients with wild-type TP53.
引用
收藏
页码:383 / 390
页数:7
相关论文
共 50 条
  • [1] TP53 germline mutations in Portugal and genetic modifiers of age at cancer onset
    Pinto, Carla
    Veiga, Isabel
    Pinheiro, Manuela
    Peixoto, Ana
    Pinto, Armando
    Lopes, Jose M.
    Reis, Rui M.
    Oliveira, Carla
    Baptista, Manuela
    Roque, Lucia
    Regateiro, Fernando
    Cirnes, Luis
    Hofstra, Robert M. W.
    Seruca, Raquel
    Castedo, Sergio
    Teixeira, Manuel R.
    FAMILIAL CANCER, 2009, 8 (04) : 383 - 390
  • [2] Germline mutations of TP53 gene in breast cancer
    Damineni, Surekha
    Rao, Vadlamudi Raghavendra
    Kumar, Satish
    Ravuri, Rajasekar Reddy
    Kagitha, Sailaja
    Dunna, Nageswara Rao
    Digumarthi, Raghunadharao
    Satti, Vishnupriya
    TUMOR BIOLOGY, 2014, 35 (09) : 9219 - 9227
  • [3] Germline mutations in the TP53 gene
    Eeles, RA
    CANCER SURVEYS, 1995, 25 : 101 - 124
  • [4] Germline TP53 mutations in women with very early onset breast cancer (BR).
    Masciari, S
    Harris, L
    Branda, K
    Petkovska, A
    Paez, J
    Haber, D
    Digianni, L
    Sellers, W
    Li, F
    Garber, J
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 109S - 109S
  • [5] Clinical implications of germline mutations in breast cancer: TP53
    Katherine Schon
    Marc Tischkowitz
    Breast Cancer Research and Treatment, 2018, 167 : 417 - 423
  • [6] Clinical implications of germline mutations in breast cancer: TP53
    Schon, Katherine
    Tischkowitz, Marc
    BREAST CANCER RESEARCH AND TREATMENT, 2018, 167 (02) : 417 - 423
  • [7] Characterization of germline TP53 splicing mutations and their genetic and functional analysis
    Varley, JM
    Attwooll, C
    White, G
    McGown, G
    Thorncroft, M
    Kelsey, AM
    Greaves, M
    Boyle, J
    Birch, JM
    ONCOGENE, 2001, 20 (21) : 2647 - 2654
  • [8] Germline TP53 mutations: the predominant genetic cause of adrenocortical carcinoma
    Renaux-Petel, M.
    Charbonnier, F.
    Tournier, I.
    Lienard, G.
    Bou, J.
    Kasper, E.
    Leheup, B.
    Mansuy, L.
    Guerrini-Rousseau, L.
    Brugieres, L.
    Liard-Zmuda, A.
    Baert-Desurmont, S.
    Frebourg, T.
    Bougeard, G.
    EUROPEAN JOURNAL OF HUMAN GENETICS, 2019, 27 : 1105 - 1105
  • [9] Characterization of germline TP53 splicing mutations and their genetic and functional analysis
    J M Varley
    C Attwooll
    G White
    G McGown
    M Thorncroft
    A M Kelsey
    M Greaves
    J Boyle
    J M Birch
    Oncogene, 2001, 20 : 2647 - 2654
  • [10] Three germline mutations in the TP53 gene
    Cornelis, RS
    vanVliet, M
    vandeVijver, MJ
    Vasen, HFA
    Voute, PA
    Top, B
    Khan, PM
    Devilee, P
    Cornelisse, CJ
    HUMAN MUTATION, 1997, 9 (02) : 157 - 163